About Us
About Gamida Cell
Leadership Team
Board of Directors
Advisory Board
Technology
NAM Technology
Selected Publications
Pipeline
Pipeline
NiCord
®
NAM-NK
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Financials & Filings
SEC Filings
Corporate Governance
Board of Directors
Leadership Team
Committee Composition
Documents & Charters
Investor Resources
Investor Contacts
Email Alerts
Contact Us
About Us
About Gamida Cell
Leadership Team
Board of Directors
Advisory Board
Technology
NAM Technology
Selected Publications
Pipeline
Pipeline
NiCord
®
NAM-NK
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Financials & Filings
SEC Filings
Corporate Governance
Board of Directors
Leadership Team
Committee Composition
Documents & Charters
Investor Resources
Investor Contacts
Email Alerts
Contact Us
Selected Publications
Dec
2018
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo with Nicotinamide
Horwitz M.E., Wease S., Blackwell B., et al.
Journal of Clinical Oncology.
2018 DOI: 10.1200/JCO.18.00053.
Dec
2018
Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution After Nicotinamide-Expanded Cord Blood Transplantation
De Koning C., Horwitz M.E., Sanz G. et al. Presented at the 2018 American Society for Hematology (ASH) Annual Meeting.
Jun
2018
Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer (NK) Cells for the Treatment of Relapsed/Refractory CD20+ non-Hodgkin Lymphoma
Bachanova V., McKenna, Jr., D.H., Luo X. et al. Presented at the 2018 International Meeting on Advances in Malignant Lymphoma.
May
2018
Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Boelens J.J. Presented at 2018 International Society for Cellular Therapy (ISCT) Annual Meeting.
Dec
2017
Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-applicable Method for NK Expansion
Peled T., Brachya G., Persi N. et al. Presented at the 2017 American Society for Hematology (ASH) Annual Meeting.
Dec
2017
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial
Horwitz M. and Sanz G. Presented at the 2017 ASH Annual Meeting.
Apr
2017
Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization
Anand S., Thomas S., Hyslop T. et al.
Biol Blood Marrow Transplant.
2017 Jul;23(7):1151-1157.
Dec
2016
Successful Engraftment and Cure of Sickle Cell Disease after Co-transplantation of NiCord® (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Children with Severe Sickle Cell Disease
Parkikh S.H., Brochstein J., Martin P.L. et al. Presented at the 2017 ASH Annual Meeting.
Dec
2016
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
Horwitz M., Montesinos P., Kurtzberg J. et al. Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
Jun
2016
Results of Nicord Phase I–II Trials and Plans for Phase III Trial
Horwitz M. Presented at the 2016 International Cord Blood Symposium.
Apr
2016
Transplantation of Ex vivo Expanded Umbilical Cord Blood (NiCord®) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days
Anand S., Thomas S., Corbet K. et al. Presented at the 2016 European Society for Blood and Marrow Transplantation (EMBT).
Oct
2013
Nicord Expands Haematopoietic Stem Cells and Provides Prompt and Durable Engraftment in Patients Undergoing Cord Blood Transplantation for Haematological Malignancies and Sickle Cell Disease: Results of Early Phase Clinical Trials Using Fresh and Crypreserved Product
Kurtzberg J., Horwitz M., Sanz G.F. et al. Presented at the 2013 European School of Haematology (ESH) Annual Meeting.
Send us a message
Name*
Email*
Country
Message*